Who we are

An integrated insulin company, built on our own science.

BioGenomics Limited was founded in 2002 by scientists with long experience in drug development, regulatory science and GMP manufacturing. We develop, manufacture and supply biosimilar insulin analogues and recombinant proteins.

2002

Founded in India by scientists

Nov 2023

Our insulin aspart in use by patients in India, as InsuQuick™

Sep 2025

Insulin aspart mix approved in India

Phase III

Insulin glargine: Phase III completed; approved by the SEC

We built every step ourselves: the strains that express our insulin, the processes that purify it, the methods that prove its quality, and the formulations that become the finished cartridge, pen or vial.

Our insulin aspart has been used by patients in India since November 2023 under the brand name of InsuQuick™. Our insulin aspart mix was approved in India in September 2025. Our insulin glargine has completed Phase III and has been approved by the Subject Expert Committee (SEC).

Strain to pen

How the pieces fit.

Step 1

Strain and cell bank

Step 2

Drug substance

India

Step 3

Drug product

India and Oman

Step 4

Regulatory dossier

Step 5

Our partner

Finally

The person who needs insulin

Vision, mission & values

What we stand for.

Our vision

Increasing access to life-saving biopharmaceuticals through adaptive innovations.

Our mission

To be a globally respected anti-diabetic biopharma brand by generating value for all its stakeholders.

Our values

Compassionate science

We pair technical precision with care for the people our work serves.

Responsible innovation

Every advance is guided by safety, quality and real need.

Unwavering quality

People who rely on insulin every day deserve nothing less than global standards.

Accessible excellence

Good science should reach everyone who needs it.

Transparency and trust

We are open about our processes, our progress and our commitments.

Our purpose & access

Insulin should not be a luxury.

Around 589 million adults worldwide live with diabetes, and many of them depend on insulin every day. Modern insulin analogues give better control and more flexibility in daily life. Yet for many people, and for many health systems, their cost remains a barrier.

We exist to lower that barrier. Because we built our technology ourselves and make our own drug substance, we can supply modern insulin analogues at a price health systems can sustain.

Source: International Diabetes Federation, IDF Diabetes Atlas, 11th edition (2025).

Access depends on more than price. It needs three things, and we commit to all three:

Reliable supply.

A person on insulin cannot wait for a shortage to resolve.

Consistent quality.

Every cartridge must be one a doctor can trust.

A sustainable price.

One that health systems can afford year after year.

India’s first launched biosimilar insulin aspart.

In 2023, USV Private Limited and BioGenomics launched InsuQuick™, India’s first launched biosimilar rapid-acting insulin aspart. We developed it with 100% indigenous technology, backed by more than 10 years of our own R&D.

10+ years

Our own R&D

We built the technology for rapid-acting insulin aspart ourselves, and the expertise to make complex biologics.

Oct 2021

Regulatory permission

India’s drug regulator granted permission for our domestically developed insulin aspart.

2023

Launch in India

USV and BioGenomics launched InsuQuick™.

Today

Three presentations

Cartridges, vials and prefilled disposable pens.

Why it mattered. It strengthened India’s own biotechnology, widened treatment choice and competition in mealtime insulin, and showed that Indian companies can develop complex biologic medicines, in line with Make in India.

“Insulin is not a cure for diabetes; it is a treatment.”

Dr. Frederick Banting, co-discoverer of insulin · Nobel Lecture, 1925

Leadership

The people who lead BioGenomics.

Dr. Sanjay Sonar

President and Co‑founder

Dr. Sonar has over 35 years of experience in protein engineering and downstream processing. He earned his Ph.D. at the Indian Institute of Technology Bombay and did postdoctoral work at Boston University and at MIT, where he worked for six years with Nobel Laureate Har Gobind Khorana. He is an inventor on more than 100 patents.

“The work matters only when it reaches the people who need it.”

Dr. Archana Rajesh Krishnan

Whole-time Director and Co‑founder

Dr. Krishnan is a Co-founder and Director at BioGenomics and leads the scientific work in genetic engineering, cloning, fermentation, and biological assays, with a core focus on translating innovative research into commercially viable biologics. She has a deep understanding of scale-up for commercial manufacturing, with over 26 years of experience. Her journey began with a strong academic foundation in Microbiology and Biochemistry, culminating in a Ph.D. in Biotechnology. An accomplished inventor, Dr. Krishnan holds more than 27 patents and numerous publications in peer reviewed scientific journals.

“I am passionate about leading scientific innovation from the laboratory to commercial manufacturing.”

Abhishek Deshpande

Chief Financial Officer

Mr. Abhishek Deshpande brings 25 years of national and international management experience. A Chartered Accountant with management studies, he oversees the company’s business operations, balancing financial discipline with operational efficiency to support growth and long-term value.

Board & governance

A board with scientific, regulatory, financial and commercial depth.

Our board includes independent directors and directors nominated by our institutional shareholders.

Dr. Archana Krishnan

Whole-time Director and Co‑founder

Rajesh Dalal

Independent Director

Former Venture Partner, OrbiMed

Rajiv Malik

Independent Director

Former CEO, Eurofins Advinus

Mohammed Hamdan Al Rubaie

Nominee Director

Former Director General, Pharmaceutical Affairs and Drug Control, Ministry of Health, Oman

Ali Abdullah Ali Al Amri

Nominee Director

Healthcare Investments, Oman Investment Authority

Imran Jamiluddin Shaikh

Nominee Director

Healthcare Lead, Oman Investment Authority

Namit Rustagi

Nominee Director

Chief Legal Counsel, MB Group

Sushil Srivastava

Nominee Director

Former CFO, MB Holding